226 related articles for article (PubMed ID: 12722392)
1. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
2. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
3. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
4. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
5. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
6. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
7. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
8. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
[TBL] [Abstract][Full Text] [Related]
9. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
11. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
12. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel premedication regimens.
Boehm DK; Maksymiuk AW
J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
[No Abstract] [Full Text] [Related]
14. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
Jeerakornpassawat D; Suprasert P
Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
Yahata H; Saito M; Sendo T; Itoh Y; Uchida M; Hirakawa T; Nakano H; Oishi R
Int J Cancer; 2006 May; 118(10):2636-8. PubMed ID: 16353140
[TBL] [Abstract][Full Text] [Related]
16. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
Zidan J; Hussein O; Abzah A; Tamam S; Farraj Z; Friedman E
Med Oncol; 2008; 25(3):274-8. PubMed ID: 18363113
[TBL] [Abstract][Full Text] [Related]
17. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
[TBL] [Abstract][Full Text] [Related]
18. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reaction to paclitaxel: nursing interventions.
Myers JS
Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
[TBL] [Abstract][Full Text] [Related]
20. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]